Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis



Rating:

Share or cite this content

Citations should be made in the following way:
R. Pereira De Matos Cordeiro (Torres Vedras, Portugal), M. Cavaco (Torres Vedras, Portugal), C. Silvestre (Torres Vedras, Portugal), A. Nunes (Torres Vedras, Portugal), J. Araújo (Torres Vedras, Portugal), P. Raimundo (Torres Vedras, Portugal), D. Duarte (Torres Vedras, Portugal), C. Cardoso (Torres Vedras, Portugal), N. André (Torres Vedras, Portugal), R. Macedo (Lisbon, Portugal), A. Domingos (Torres Vedras, Portugal). LTBI - MDR/XDR-TB cases - should all be treated?. 3344

Member's Comments

No comment yet.

Related content which might interest you: MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Range of additional drug resistance of M.tuberculosis in XDR-TB patients Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 The risk of tuberculosis in HIV infected in the 12 years of observation Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015 The feature of BCG complications in children Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013 Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 The particularities of new cases of tuberculosis at homeless people Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Tuberculosis (TB), mortality - efficiency of new control / treatment strategies Source: Annual Congress 2003 - Control of tuberculosis Year: 2003 The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 New-immigrant screening for latent tuberculosis infection: Reasons for non-treatment Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Particularities of tuberculosis in children aged 0-3 years Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Influence of early diagnostics with Xpert MTB/RIF on MDR TB patients treatment efficacy Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015